OBSEF (ObsEva) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


OBSEF ObsEva SA OBSEF
18 GF Score
Price $0.00
View Full Analysis

What is ObsEva Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ObsEva's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OBSEF vs VRTX, REGN, SGEN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, ObsEva's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ObsEva Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where ObsEva's Margin of Safety % (DCF Earnings Based) falls into.


OBSEF
18GF Score
ObsEva SA OBSEF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ObsEva Business Description

Address Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
18GF Score

Get the complete analysis for OBSEF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price